Drug Chatter -- Tracking biopharma stock chatter

Profile for Exelixis, Inc. (EXEL)

« Back to company index

EXEL Chatter Timeline

Stock Ticker for EXEL

Most Active Tweeters for EXEL

UserTweets
@TickerReport 7
@intercooleronli 7
@SPNewsAnalysis 6
@Bizquick 6
@DrTranBioSci 5

Recent Tweets for EXEL

allincapital @allincapital
25 handle I'll circle back on $EXEL https://t.co/DJ0yynmWFG
July 27th 2017, 10:07pm
RatingsNetwork @RatingsNetwork
Exelixis's outperform rating reiterated at William Blair. https://t.co/ZGuP8BVOwS $EXEL #EXEL
July 27th 2017, 4:07pm
stockassassin74 @stockassassin74
@stefanomjr $tsro more likely to be next $exel
July 27th 2017, 8:07am
Afolleso @Afolleso
@pick1998_2 $MBVX My opinion: bankrupt or the next $EXEL x 2. Of course, they could be bought out early. Distressed financials.
July 27th 2017, 3:07am
DrTranBioSci @DrTranBioSci
Exelixis gained +2.28% today: this aggressive grower is riding on the wings of the cabozantinib franchises. $EXEL https://t.co/NN4MTkXkLo
July 26th 2017, 5:07pm
finboxio @finboxio
Our Exelixis, $EXEL fundamental analysis highlights stock's 20% undervalued b4 earnings next Wednesday… https://t.co/M8LFZZi6gx
July 26th 2017, 3:07pm
Bizquick @Bizquick
$EXEL INSTITUTIONS TAKING PROFITS...FYI
July 26th 2017, 2:07pm
Bizquick @Bizquick
$EXEL expecting a pullback
July 26th 2017, 12:07pm
Bizquick @Bizquick
$EXEL if it dips below 27.85 it will probably go lower...imo
July 26th 2017, 12:07pm
storminvestor @storminvestor
Exelixis, Inc. $EXEL Lowered to “Hold” at Zacks Investment Research https://t.co/h3cEz2KsVG
July 25th 2017, 8:07pm
SPNewsAnalysis @SPNewsAnalysis
Exelixis, Inc. $EXEL Lowered to “Hold” at Zacks Investment Research https://t.co/fed79zbCH1
July 25th 2017, 8:07pm
midetimes @midetimes
Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Exelixis $EXEL Share Price https://t.co/Grp4Y0obN7
July 25th 2017, 6:07pm
TheMarketsDaily @TheMarketsDaily
Exelixis $EXEL Receiving Somewhat Favorable Media Coverage, Study Finds https://t.co/2HW3XW63Fj
July 25th 2017, 6:07pm
dailypoliticaln @dailypoliticaln
Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Exelixis $EXEL Share Price https://t.co/4PNwGYPGqk
July 25th 2017, 6:07pm
SleekMoneycom @SleekMoneycom
Exelixis, Inc. Expected to Post FY2019 Earnings of $1.54 Per Share $EXEL https://t.co/x7HhOUDSSC
July 25th 2017, 4:07pm
dailypoliticaln @dailypoliticaln
Exelixis, Inc. $EXEL Shares Sold by Insight Capital Research & Management Inc. https://t.co/tKCLDFegQC
July 25th 2017, 2:07pm
TheMarketsDaily @TheMarketsDaily
Insight Capital Research & Management Inc. Has $2.41 Million Position in Exelixis, Inc. $EXEL https://t.co/ruWoy6TZ6H
July 25th 2017, 2:07pm
DrTranBioSci @DrTranBioSci
Exelixis is excelling w/+3.23% gains for the day. Cabozantinib is stellar & will deliver substantial profits. $EXEL https://t.co/NN4MTkXkLo
July 24th 2017, 5:07pm
IRAMarketReport @IRAMarketReport
Short Interest in Exelixis, Inc. $EXEL Drops By 8.1% https://t.co/ZPb2HogcP0
July 24th 2017, 4:07pm
chaffeybreeze @chaffeybreeze
Short Interest in Exelixis, Inc. $EXEL Drops By 8.1% https://t.co/vA9oqjaqbw
July 24th 2017, 4:07pm
ITRADEVOL @ITRADEVOL
$EXEL Exelixis Best/Worst Trading Hour Summary (20 Day) https://t.co/IwGSsIcbeH
July 24th 2017, 1:07pm
JXMfinance @JXMfinance
$EXEL is working on a 10% July. https://t.co/BSniIVKAgS
July 24th 2017, 1:07pm
CashRocket @CashRocket
Beautiful little trade for 40% gains in $EXEL, props to @OptionsHawk for flagging sale of 3K Aug 25P on 7/19 as a t… https://t.co/g2ovXLATAw
July 24th 2017, 1:07pm
1MinuteStock @1MinuteStock
Unicorn Bay rating for $EXEL is 2.83 out of 5. https://t.co/Lw8PCl4AEv
July 24th 2017, 12:07pm
artworktrades @artworktrades
RT @TMLTrader: $EXEL back at multi-year high after a brief pullback to its 10-day MA. https://t.co/NvqjYp0QZD
July 24th 2017, 12:07pm
TMLTrader @TMLTrader
$EXEL back at multi-year high after a brief pullback to its 10-day MA. https://t.co/NvqjYp0QZD
July 24th 2017, 12:07pm
CashRocket @CashRocket
$EXEL new YTD highs ahead of 8/2 EPS. Cabo estimates are still too low. CELESTIAL Phase 3 data also expected 2H17.
July 24th 2017, 11:07am
vivazapata173 @vivazapata173
$EXEL Take a look at AVEO. Tivozanib Recommended for Approval in EU for Renal Cell Carcinoma. Approval date end of Aug Accumulating now.
July 24th 2017, 11:07am
tinmanken @tinmanken
$EXEL to test 28.00
July 24th 2017, 11:07am
intercooleronli @intercooleronli
FY2019 Earnings Estimate for Exelixis, Inc. $EXEL Issued By Leerink Swann https://t.co/sNzmu04h4z
July 24th 2017, 11:07am
SleekMoneycom @SleekMoneycom
Meeder Asset Management Inc. Purchases 2,091 Shares of Exelixis, Inc. $EXEL https://t.co/MiX6J6gaOe
July 24th 2017, 10:07am
rosderek @rosderek
@TBowers77 And updated Cobi cost / rev split w Genentech should add solid value to cobi franchise for $exel, value was murky in the past
July 23rd 2017, 6:07pm
SleekMoneycom @SleekMoneycom
Exelixis, Inc. Forecasted to Earn FY2018 Earnings of $0.66 Per Share $EXEL https://t.co/57ggJTTa2s
July 23rd 2017, 8:07am
clarklsn2001 @clarklsn2001
@ohmsonite Thoughts on the what could be the next baby $exel?
July 22nd 2017, 6:07pm
YuZhu4 @YuZhu4
RT @RNAiAnalyst: $EXEL an example of biotech w/ strong scientific base where it was mainly matter of time 'til they hit a home-run. https:/…
July 22nd 2017, 4:07pm
RNAiAnalyst @RNAiAnalyst
$EXEL an example of biotech w/ strong scientific base where it was mainly matter of time 'til they hit a home-run. https://t.co/WJRp4H6GTZ
July 22nd 2017, 4:07pm
portefeuillefun @portefeuillefun
RT @ohmsonite: Finally sold the last chunk of $EXEL. Really happy with my patience with this company - 530% long term gain. Wish I have mor…
July 22nd 2017, 4:07pm
ohmsonite @ohmsonite
Finally sold the last chunk of $EXEL. Really happy with my patience with this company - 530% long term gain. Wish I have more of those, ha!
July 22nd 2017, 3:07pm
IRAMarketReport @IRAMarketReport
Exelixis, Inc. to Post FY2018 Earnings of $0.66 Per Share, Leerink Swann Forecasts $EXEL https://t.co/SmmKygX2aq
July 22nd 2017, 12:07pm
TickerReport @TickerReport
William Blair Comments on Exelixis, Inc.’s FY2018 Earnings $EXEL https://t.co/iXVQIt4ldH
July 22nd 2017, 12:07pm
biotech_sector @biotech_sector
#Exelixis Bristol-Myers Squibb (BMY) & Exelis Commence Phase 3 Trial of Opdivo in Combinati... Read more: https://t.co/M6yJ9oN0cb $EXEL
July 22nd 2017, 11:07am
WeekHerald @WeekHerald
Exelixis, Inc. to Post FY2018 Earnings of $0.66 Per Share, Leerink Swann Forecasts $EXEL https://t.co/KRZl7xDLNy
July 22nd 2017, 11:07am
WeekHerald @WeekHerald
William Blair Comments on Exelixis, Inc.’s FY2018 Earnings $EXEL https://t.co/sQo7yeaATW
July 22nd 2017, 11:07am
astruzynski @astruzynski
$EXEL weekly. Inside week week https://t.co/3QinALmokl
July 22nd 2017, 6:07am
AlertTrade @AlertTrade
#SwingTradeAlert $EXEL technical alerts: Stochastic Reached Overbought, Narrow Range… https://t.co/Iln3zOP0Zn via ? https://t.co/3vJdaf0nJa
July 22nd 2017, 5:07am
SwingTradeBot @SwingTradeBot
$EXEL technical alerts: Stochastic Reached Overbought, Narrow Range Bar, NR7-2, and NR7 https://t.co/R8mMMMOolt
July 22nd 2017, 5:07am
Bizquick @Bizquick
@nobullshytrader That sucks bro short $EXEL THEN LOL
July 21st 2017, 8:07pm
dailymailtimes @dailymailtimes
Exelixis’ $EXEL Hold Rating Reaffirmed at Cann https://t.co/ejbmNm3gqK
July 21st 2017, 7:07pm
storminvestor @storminvestor
Exelixis’ $EXEL Hold Rating Reaffirmed at Cann https://t.co/Izp7nDqu7N
July 21st 2017, 7:07pm
SPNewsAnalysis @SPNewsAnalysis
Exelixis’ $EXEL Hold Rating Reaffirmed at Cann https://t.co/KI8XCpVI52
July 21st 2017, 7:07pm

Contact © thinkBiotech LLC 2004 - 2017. All rights reserved.